Exenatide
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronary Artery Disease
Conditions
Coronary Artery Disease, Decreased Left Ventricular Function
Trial Timeline
Jun 1, 2011 → Dec 1, 2014
NCT ID
NCT01373216About Exenatide
Exenatide is a phase 3 stage product being developed by Eli Lilly for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01373216. Target conditions include Coronary Artery Disease, Decreased Left Ventricular Function.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01373216 | Phase 3 | Completed |
| NCT01056549 | Pre-clinical | Completed |
| NCT00753896 | Phase 3 | Completed |
| NCT00529204 | Phase 2 | Terminated |
| NCT00516048 | Phase 3 | Completed |
| NCT01876849 | Phase 3 | Completed |
Competing Products
20 competing products in Coronary Artery Disease